Lv2
200 积分 2024-12-04 加入
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1天前
待确认
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
1天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1天前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
27天前
已完结
Evolution of TROP2: Biological insights and clinical applications
2个月前
已完结
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
2个月前
已完结
Trastuzumab deruxtecan in breast cancer
3个月前
已完结
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
3个月前
已完结
HER2-targeted therapies beyond breast cancer — an update
3个月前
已完结
Updates in Treatment of HER2-positive Metastatic Breast Cancer
3个月前
已完结
皖公网安备34019202002308
